The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - Ipsen; Xencor; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); ArQule (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Onco Response (Inst); Purple Biotech (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; Jazz Pharmaceuticals; Mirati Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Biothera (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Raghad Muhsin Abdul-Karim
Research Funding - Adagene (Inst); Amphivena Therapeutics, Inc. (Inst); Basilea (Inst); Birdie (Inst); BJ Bioscience (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); InhibRx (Inst); ORIC Pharmaceuticals (Inst); Petra Pharma (Inst); Pfizer (Inst); Spring Bank (Inst); Synthorx (Inst); Takeda (Inst)
 
Vincent Chung
Consulting or Advisory Role - Perthera; Pfizer
Speakers' Bureau - AstraZeneca; Coherus Biosciences; Ipsen
Research Funding - Merck (Inst)
 
Craig E. Devoe
Honoraria - Pfizer; Vivacitas Oncology
Consulting or Advisory Role - Pfizer
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncorus (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Turning Point Therapeutics (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Alexis Diane Leal
Employment - Elsevier
Leadership - Elsevier
Research Funding - Abbvie (Inst); Arrys Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conjupro Biotherapeutics (Inst); Corcept Therapeutics (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Takeda (Inst)
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Esther Welkowsky
Employment - Elicio Therapeutics
Stock and Other Ownership Interests - Elicio Therapeutics
Consulting or Advisory Role - Allogene Therapeutics
Research Funding - Elicio Therapeutics
 
Christopher M. Haqq
Employment - Elicio Therapeutics
Leadership - Consonance HFW SPAC; Elicio Therapeutics
Stock and Other Ownership Interests - Atara Biotherapeutics; Elicio Therapeutics; Janssen
Consulting or Advisory Role - Atara Biotherapeutics
Research Funding - Elicio Therapeutics
Patents, Royalties, Other Intellectual Property - Amgen; Atara Biotherapeutics; Elicio Therapeutics; University of California- San Francisco
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca (I); Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen (I); Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
 
Colin D. Weekes
Honoraria - Bayer; Celgene; Lilly
Consulting or Advisory Role - Celgene; Ipsen; Merrimack
Research Funding - Abbvie; Actuate Therapeutics; AstraZeneca; Bayer; Celgene; Dicephera Pharmaceuticals, Inc.; Genentech/Roche; Gilead Sciences; Halozyme; Ipsen; Lilly; Millennium; Novartis
Travel, Accommodations, Expenses - Bayer; Celgene; Lilly